NASDAQ:CGEN
Compugen Ltd. Stock News
$2.14
-0.0700 (-3.17%)
At Close: May 16, 2024
Compugen Announces Publication of a Peer Reviewed Paper on its Cancer Immunology Research
12:00am, Monday, 20'th Apr 202070 Biggest Movers From Yesterday
08:53am, Friday, 17'th Apr 2020
Gainers
Arcus Biosciences, Inc. (NASDAQ: RCUS) shares surged 89.4% to close at $29.50 on Thursday amid Bloomberg report that Gilead is holding talks to take a stake in company....
52 Stocks Moving In Thursday's Mid-Day Session
04:58pm, Thursday, 16'th Apr 2020
Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares climbed 167.8% to $92.90.
Edison Nation Inc (NASDAQ: EDNT) shares climbed 97.6% to $3.30 after the company...
52 Stocks Moving In Thursday's Mid-Day Session
04:57pm, Thursday, 16'th Apr 2020
Gainers
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares climbed 167.8% to $92.90.
Edison Nation Inc (NASDAQ: EDNT) shares climbed 97.6% to $3.30 after the company...
Cancer Drug Maker Arcus Surgesas Street Touts$10 Billion Opportunity With Gilead
04:24pm, Thursday, 16'th Apr 2020
(Bloomberg) -- Arcus Biosciences Inc., which is working in a category of new cancer medicines estimated to be worth as much $10 billion, nearly doubled after Bloomberg reported that Gilead Sciences In
Stocks That Hit 52-Week Highs On Thursday
02:19pm, Thursday, 16'th Apr 2020
On Thursday morning, 49 companies hit new 52-week highs.
Noteworthy Mentions:
Amazon.com (NASDAQ: AMZN) was the largest firm on a market cap basis to set a new 52-week...
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
11:00am, Tuesday, 14'th Apr 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will present updates on its ongoing Phase 1 clinical tr
Zacks Investment Research Downgrades Compugen (NASDAQ:CGEN) to Hold
10:50am, Sunday, 12'th Apr 2020
Zacks Investment Research cut shares of Compugen (NASDAQ:CGEN) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, “Compugen Ltd. is
Compugen (NASDAQ:CGEN) Upgraded at BidaskClub
10:10am, Sunday, 12'th Apr 2020
BidaskClub upgraded shares of Compugen (NASDAQ:CGEN) from a buy rating to a strong-buy rating in a report issued on Thursday morning, BidAskClub reports. A number of other brokerages have also recentl
Compugen (NASDAQ:CGEN) Upgraded to "Buy" at Zacks Investment Research
10:04am, Tuesday, 07'th Apr 2020
Zacks Investment Research upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research note released on Monday, Zacks.com reports. The brokerage currently has $8.25 price
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
11:00am, Monday, 06'th Apr 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical t
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
12:00am, Monday, 06'th Apr 2020Compugen Ltd. (NASDAQ:CGEN) Shares Sold by Jane Street Group LLC
11:06am, Saturday, 04'th Apr 2020
Jane Street Group LLC reduced its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 16.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 85,173 shares of the biot
Blair likes Incyte in premarket analyst action
11:53am, Tuesday, 24'th Mar 2020
Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares u
